CA-CLICKHOUSE
25.6.2024 17:46:36 CEST | Business Wire | Press release
ClickHouse Inc, a leader in real-time analytics, announces the expansion of ClickHouse Cloud to Microsoft Azure, providing users with even more options for deploying and managing their analytics workloads. With this expansion, ClickHouse Cloud is now available on three major cloud service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625765046/en/
ClickHouse Cloud is now generally available on Microsoft Azure (Graphic: Business Wire)
As organizations increasingly adopt real-time analytics databases in their interactive, data-driven customer-facing applications, as well as in their internal data warehousing and data science workflows, ClickHouse Cloud availability on Azure offers customers greater flexibility and choice. Availability of ClickHouse Cloud in Azure Marketplace allows users to use existing Azure investments and take advantage of integrations with Azure-specific services including Microsoft Power BI and Azure Event Hubs.
“Companies of all sizes trust ClickHouse to gain valuable insights from their data, across a wide variety of use cases,” says Aaron Katz, Co-founder and CEO of ClickHouse, Inc. “This announcement reiterates our vision to bring the best real-time data warehouse to our users regardless of which cloud provider they use.”
“With ClickHouse Cloud generally available on Microsoft Azure, enterprise and digital-native companies alike can take advantage of its breadth of use cases on one of the most open and flexible cloud platforms,” said Erin Chapple, corporate vice president, Azure Core Products and Design at Microsoft. “Mutual customers and partners can now benefit from real-time analytics and business intelligence solutions to gain valuable insights from their data in new ways.”
Public Beta for ClickHouse Cloud on Azure was announced at Microsoft Build in May 2024 and is seeing strong adoption across organizations looking to build real-time analytical applications on top of Azure.
"We are thrilled about the launch of ClickHouse Cloud on Microsoft Azure," said Julian LaNeve, Chief Technology Officer at Astronomer. "Our data platform handles massive volumes of real-time events, and ClickHouse has been instrumental in delivering lightning-fast analytics. With ClickHouse Cloud on Azure, we can deploy and scale effortlessly on Azure's reliable, secure, and scalable infrastructure."
“At BaxEnergy, our mission is to make renewable energy easier, more efficient, affordable, and secure," said Marco Cecconi, Head of R&D of BaxEnergy. “ClickHouse Cloud on Microsoft Azure supports us in conducting advanced analysis on large volumes of data from various renewable energy sources. By generating actionable insights, creating detailed reports, and developing custom dashboards, we empower our customers to achieve better performance and scale their operations effectively. We have been pleasantly surprised by the remarkable speed and flexibility of ClickHouse, and their team has provided us with exceptional dedicated support.”
Some additional benefits of using ClickHouse Cloud on Azure include:
Simplicity. With ClickHouse Cloud, you create your service with a single click. You don't have to worry about the operational complexity of server configurations and cluster topology, shards and replicas, managing backups and restores, durability and fault tolerance, monitoring, or alerts. It just works.
Speed and Scale. ClickHouse Cloud is designed to handle real-time analytics on top of petabyte-scale datasets. There is no need for manual sharding or data movement, as it scales automatically. Our multi-layer cache and other cloud-native performance optimizations ensure impressive query performance for a wide variety of workloads.
Security and Reliability. ClickHouse Cloud has security best practices built in by default. It is configured with network isolation and traffic encryption. ClickHouse builds are additionally hardened, tested, and validated for ClickHouse Cloud. The service is automatically replicated across multiple availability zones for high availability.
Efficiency. ClickHouse Cloud adapts itself to the changing nature of your workloads, scaling up and down as needed. ClickHouse Cloud also takes advantage of shared object storage as its primary storage, while separating compute resources. This dramatically increases flexibility and resource efficiency, delivering industry's best price/performance ratio.
Ecosystem. Easy-to-use integrations allow users to seamlessly ingest data and interface with internal and external systems. A curated set of core and partner integrations vetted to work seamlessly with ClickHouse Cloud are provided in addition to hundreds of community-built integrations. Within the Azure ecosystem, ClickHouse Cloud features turnkey integrations with Azure Event Hubs, Power BI, and Azure Blob Storage.
ClickHouse Cloud offers a 30-day trial that includes $300 free usage credits. To get started, sign up here or subscribe from Azure Marketplace.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625765046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom